Swiss National Bank Acquires 13,600 Shares of Insulet Corporation $PODD

Swiss National Bank boosted its stake in shares of Insulet Corporation (NASDAQ:PODD) by 7.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 206,500 shares of the medical instruments supplier’s stock after buying an additional 13,600 shares during the period. Swiss National Bank’s holdings in Insulet were worth $43,332,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of PODD. Glenmede Investment Management LP increased its holdings in shares of Insulet by 1.6% in the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 35 shares during the period. Curi Capital LLC boosted its position in Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after purchasing an additional 36 shares in the last quarter. Great Lakes Advisors LLC grew its stake in Insulet by 1.5% in the fourth quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock valued at $791,000 after purchasing an additional 40 shares during the last quarter. Camarda Financial Advisors LLC grew its stake in Insulet by 0.5% in the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after purchasing an additional 40 shares during the last quarter. Finally, Larson Financial Group LLC grew its stake in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the last quarter.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Negative Sentiment: Multiple law firms announced or reminded investors about a recently filed securities fraud class action against Insulet, with claims tied to alleged misstatements about Omnipod safety and manufacturing practices. The filings cite two recalls affecting millions of pods and say the issues may have hurt investors who bought shares during the class period. Article Title
• Negative Sentiment: The lawsuit coverage suggests investors are still digesting the fallout from prior recalls and related stock declines, and firms are encouraging shareholders to seek lead-plaintiff roles before the August 31 deadline. Article Title
• Neutral Sentiment: One item noted that analysts still expect double-digit earnings growth ahead of Insulet’s next quarterly report, which provides a potential longer-term offset to the legal headlines. Article Title

Analysts Set New Price Targets

Several analysts have commented on PODD shares. Benchmark reissued a “buy” rating on shares of Insulet in a research report on Wednesday, May 27th. Robert W. Baird cut their price objective on shares of Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Evercore set a $180.00 price objective on shares of Insulet in a research note on Monday, July 6th. Barclays decreased their target price on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research report on Thursday, May 7th. Finally, Truist Financial lowered their target price on shares of Insulet from $219.00 to $210.00 and set a “buy” rating for the company in a research note on Monday, July 13th. Twenty-two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $235.25.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.36% of the stock is owned by insiders.

Insulet Trading Down 2.9%

Shares of NASDAQ:PODD opened at $158.93 on Thursday. The business’s 50-day moving average is $153.58 and its 200 day moving average is $203.76. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. Insulet Corporation has a 1 year low of $138.79 and a 1 year high of $354.88. The firm has a market capitalization of $11.01 billion, a P/E ratio of 36.96, a P/E/G ratio of 1.14 and a beta of 1.11.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same quarter last year, the company earned $1.02 earnings per share. The company’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts predict that Insulet Corporation will post 6.45 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.